| Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link |
|---|---|---|---|---|---|---|
| 2014 | Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence | CHUN-JEN LIU ; Chang J.; Lee P.-H.; Lin D.-Y.; Wu C.-C.; Jeng L.-B.; Lin Y.-J.; Mok K.-T.; Lee W.-C.; Yeh H.-Z.; Ho M.-C.; Yang S.-S.; Yang M.-D.; Yu M.-C.; Hu R.-H.; Peng C.-Y.; Lai K.-L.; Chang S.S.-C.; Chen P.-J. | World Journal of Gastroenterology | 43 | ||
| 2014 | Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence | Liu C.-J.; Chang J.; PO-HUANG LEE ; Lin D.-Y.; Wu C.-C.; Jeng L.-B.; Lin Y.-J.; Mok K.-T.; Lee W.-C.; Yeh H.-Z.; Ho M.-C.; Yang S.-S.; Yang M.-D.; Yu M.-C.; Hu R.-H.; Peng C.-Y.; Lai K.-L.; Chang S.S.-C.; Chen P.-J. | World Journal of Gastroenterology | 43 | ||
| 2014 | Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence | Liu C.-J.; Chang J.; Lee P.-H.; Lin D.-Y.; Wu C.-C.; Jeng L.-B.; Lin Y.-J.; Mok K.-T.; Lee W.-C.; Yeh H.-Z.; Ho M.-C.; Yang S.-S.; Yang M.-D.; Yu M.-C.; REY-HENG HU ; Peng C.-Y.; Lai K.-L.; Chang S.S.-C.; Chen P.-J. | World Journal of Gastroenterology | 41 | 43 | |
| 2014 | Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence | Liu C.-J.; Chang J.; Lee P.-H.; Lin D.-Y.; Wu C.-C.; Jeng L.-B.; Lin Y.-J.; Mok K.-T.; Lee W.-C.; Yeh H.-Z.; MING-CHIH HO ; Yang S.-S.; Yang M.-D.; Yu M.-C.; Hu R.-H.; Peng C.-Y.; Lai K.-L.; Chang S.S.-C.; Chen P.-J. | World Journal of Gastroenterology | 41 | 43 | |
| 2014 | Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence | Liu C.-J.; Chang J.; Lee P.-H.; Lin D.-Y.; Wu C.-C.; Jeng L.-B.; Lin Y.-J.; Mok K.-T.; Lee W.-C.; Yeh H.-Z.; Ho M.-C.; Yang S.-S.; Yang M.-D.; Yu M.-C.; Hu R.-H.; Peng C.-Y.; Lai K.-L.; Chang S.S.-C.; PEI-JER CHEN | World Journal of Gastroenterology | 43 | ||
| 2013 | Adverse outcomes after noncardiac surgery in patientswith diabetes: A nationwide population-based retrospective cohort study | Yeh C.-C.; Liao C.-C.; YI-CHENG CHANG ; Jeng L.-B.; Yang H.-R.; Shih C.-C.; Chen T.-L. | Diabetes Care | 50 | 49 | |
| 2010 | Anatomical Asymmetry in Goiter: A Demonstration by Three-dimensional Power Doppler Ultrasound | Hsieh M.-H.; Chiou S.-C.; Chen C.-C.; Hsu W.-H.; Jeng L.-B.; YI-CHENG CHANG ; Lin J.-D. | Journal of Medical Ultrasound | 0 | 0 | |
| 2013 | Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: Results from the randomized phase III BRISK-FL study | Johnson P.J.; Qin S.; Park J.-W.; Poon R.T.P.; Raoul J.-L.; Philip P.A.; CHIH-HUNG HSU ; Hu T.-H.; Heo J.; Xu J.; Lu L.; Chao Y.; Boucher E.; Han K.-H.; Paik S.-W.; Robles-Aviña J.; Kudo M.; Yan L.; Sobhonslidsuk A.; Komov D.; Decaens T.; Tak W.-Y.; Jeng L.-B.; Liu D.; Ezzeddine R.; Walters I.; Cheng A.-L. | Journal of Clinical Oncology | 542 | 542 | |
| 2013 | Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: Results from the randomized phase III BRISK-FL study | Johnson P.J.; Qin S.; Park J.-W.; Poon R.T.P.; Raoul J.-L.; Philip P.A.; Hsu C.-H.; Hu T.-H.; Heo J.; Xu J.; Lu L.; Chao Y.; Boucher E.; Han K.-H.; Paik S.-W.; Robles-Avi?a J.; Kudo M.; Yan L.; Sobhonslidsuk A.; Komov D.; Decaens T.; Tak W.-Y.; Jeng L.-B.; Liu D.; Ezzeddine R.; Walters I.; ANN-LII CHENG | Journal of Clinical Oncology | 542 | ||
| 2009 | Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and optimal dosage | CHUN-JEN LIU ; Lee P.-H.; Lin D.-Y.; Wu C.-C.; Jeng L.-B.; Lin P.-W.; Mok K.-T.; Lee W.-C.; Yeh H.-Z.; Ho M.-C.; Yang S.-S.; Lee C.-C.; Yu M.-C.; Hu R.-H.; Peng C.-Y.; Lai K.-L.; Chang S.S.-C.; Chen P.-J. | Journal of Hepatology | 114 | ||
| 2009 | Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and optimal dosage | Liu C.-J.; PO-HUANG LEE ; Lin D.-Y.; Wu C.-C.; Jeng L.-B.; Lin P.-W.; Mok K.-T.; Lee W.-C.; Yeh H.-Z.; Ho M.-C.; Yang S.-S.; Lee C.-C.; Yu M.-C.; Hu R.-H.; Peng C.-Y.; Lai K.-L.; Chang S.S.-C.; Chen P.-J. | Journal of Hepatology | 114 | ||
| 2009 | Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and optimal dosage | Liu C.-J.; Lee P.-H.; Lin D.-Y.; Wu C.-C.; Jeng L.-B.; Lin P.-W.; Mok K.-T.; Lee W.-C.; Yeh H.-Z.; Ho M.-C.; Yang S.-S.; Lee C.-C.; Yu M.-C.; REY-HENG HU ; Peng C.-Y.; Lai K.-L.; Chang S.S.-C.; Chen P.-J. | Journal of Hepatology | 114 | 114 | |
| 2009 | Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and optimal dosage | Liu C.-J.; Lee P.-H.; Lin D.-Y.; Wu C.-C.; Jeng L.-B.; Lin P.-W.; Mok K.-T.; Lee W.-C.; Yeh H.-Z.; MING-CHIH HO ; Yang S.-S.; Lee C.-C.; Yu M.-C.; Hu R.-H.; Peng C.-Y.; Lai K.-L.; Chang S.S.-C.; Chen P.-J. | Journal of Hepatology | 114 | 114 | |
| 2009 | Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and optimal dosage | Liu C.-J.; Lee P.-H.; Lin D.-Y.; Wu C.-C.; Jeng L.-B.; Lin P.-W.; Mok K.-T.; Lee W.-C.; Yeh H.-Z.; Ho M.-C.; Yang S.-S.; Lee C.-C.; Yu M.-C.; Hu R.-H.; Peng C.-Y.; Lai K.-L.; Chang S.S.-C.; PEI-JER CHEN | Journal of Hepatology | 114 | ||
| 2013 | Hepatic resection for hepatocellular carcinoma patients on hemodialysis for Uremia: A nationwide cohort study | Yeh C.-C.; Lin J.-T.; Jeng L.-B.; Charalampos I.; Chen T.-T.; Lee T.-Y.; MING-SHIANG WU ; Kuo K.N.; Liu Y.-Y.; Wu C.-Y. | World Journal of Surgery | 15 | 17 | |
| 2012 | Long-term results of a randomized, observation-controlled, phase III Trial of Adjuvant Interferon alfa-2b in hepatocellular carcinoma after curative resection | Chen L.-T.; Chen M.-F.; Li L.-A.; PO-HUANG LEE ; Jeng L.-B.; Lin D.-Y.; Wu C.-C.; Mok K.-T.; Chen C.-L.; Lee W.-C.; Chau G.-Y.; Chen Y.-S.; Lui W.-Y.; Hsiao C.-F.; Whang-Peng J.; Chen P.-J. | Annals of Surgery | 96 | 92 | |
| 2012 | Long-term results of a randomized, observation-controlled, phase III Trial of Adjuvant Interferon alfa-2b in hepatocellular carcinoma after curative resection | Chen L.-T.; Chen M.-F.; Li L.-A.; Lee P.-H.; Jeng L.-B.; Lin D.-Y.; Wu C.-C.; Mok K.-T.; Chen C.-L.; Lee W.-C.; Chau G.-Y.; Chen Y.-S.; Lui W.-Y.; Hsiao C.-F.; Whang-Peng J.; PEI-JER CHEN | Annals of Surgery | 92 | ||
| 2015 | Long-term risk of acute coronary syndrome in splenectomized patients due to splenic injury | Tsai M.-S.; Chou S.-E.; HONG-SHIEE LAI ; Jeng L.-B.; Lin C.-L.; Kao C.-H. | Medicine (United States) | 6 | 8 | |
| 2015 | Nonsteroidal anti-inflammatory drugs are associated with reduced risk of early hepatocellular carcinoma recurrence after curative liver resection: A nationwide cohort study | Yeh C.-C.; Lin J.-T.; Jeng L.-B.; Ho H.J.; Yang H.-R.; MING-SHIANG WU ; Kuo K.N.; Wu C.-Y. | Annals of Surgery | 33 | 31 | |
| 2008 | Osteoblast-derived TGF-β1 stimulates IL-8 release through AP-1 and NF-κB in human cancer cells | Fong Y.-C.; Maa M.-C.; Tsai F.-J.; Chen W.-C.; Lin J.-G.; Jeng L.-B.; RONG-SEN YANG ; Fu W.-M.; Tang C.-H. | Journal of Bone and Mineral Research | 33 | 29 |
